Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Here’s Why

Pharming Group (NASDAQ:PHAR) saw an uptick in trading volume on Monday . 5,632 shares traded hands during trading, a decline of 9% from the previous session’s volume of 6,179 shares.The stock last traded at $8.39 and had previously closed at $8.65.

Analysts Set New Price Targets

A number of research firms recently weighed in on PHAR. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer upped their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research note on Friday, March 14th. Finally, Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company.

Pharming Group Price Performance

The firm has a 50-day moving average of $8.74 and a 200 day moving average of $8.69. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company has a market capitalization of $565.34 million, a PE ratio of -31.96 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to analysts’ expectations of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.